New Nasal Spray, Noctiva, Reduces Nighttime Urination
A nasal spray formulation of desmopressin acetate, effective at reducing the number of times adults have to urinate during the night, has been approved by the U.S. Food and Drug Administration.
Noctiva (desmopressin acetate) is a nasal spray for adults who make at least two nighttime trips to the bathroom due to causes such as certain medications, chronic heart failure, poorly controlled diabetes, and bladder and prostate problems, the Associated Press reported.
The spray, used about 30 minutes before bedtime each night, helps the kidneys absorb more water in order to reduce the amount of urine.
Noctiva carries a black box warning -- the FDA's strongest -- about the risk of dangerously low levels of sodium in the blood. Other possible side effects include colds, bronchitis, a rise in blood pressure, dizziness, back pain and nose bleeds, the AP reported.
The drug was developed by Serenity Pharmaceuticals LLC and Allergan PLC.
Posted: March 2017